Mycovia Pharmaceuticals Debuts with Initiation of Phase 3 Clinical Trials for Treatment of Recurrent Vulvovaginal Candidiasis

Durham, NC – September 6, 2018 – Mycovia Pharmaceuticals, making its official debut as a company developing therapies in women’s health and dermatology, today announced the initiation of
two Phase 3 clinical trials called VIOLET to evaluate the safety and efficacy of its lead candidate, VT-1161, in patients with recurrent vulvovaginal candidiasis (RVVC).